Journal
Discover Oncology
Discover Oncology is an open access journal publishing content that interfaces at all levels of cancer research.
Lung cancer is a leading cause of cancer-related mortality, with Small Cell Lung Cancer (SCLC) being the most aggressive form. SCLC is characterized by rapid growth, high metastasis, and significant drug resistance, resulting in a poor survival rate. As a neuroendocrine tumor, SCLC's lack of comprehensive classification has hindered both basic and clinical advancements. The scarcity of tissue samples, due to the rapid clinical deterioration of relapsed patients, has impeded the molecular characterization of SCLC. Consequently, the genomic and transcriptomic landscapes, along with the mechanisms mediating therapeutic resistance, remain largely unknown.
A significant challenge in treating SCLC is resistance to advanced therapies. The absence of antigen presentation by tumor cells and an immune-cold tumor microenvironment limit the efficacy of targeted therapy, immunotherapy, and chemotherapy. The mechanisms guiding treatment decisions and prognosis evaluations in SCLC are poorly understood, creating a knowledge gap that obstructs clinical research and the development of effective treatment strategies.
This Collection seeks research on SCLC that integrates multi-omics analyses, including genomics, transcriptomics, proteomics, and metabolomics, to elucidate the molecular architecture of SCLC. Understanding therapeutic vulnerabilities and enhancing the efficacy of immunotherapy in SCLC are key goals. We invite original research and review articles on novel therapeutic targets, signalling pathways, biomarker discovery, and resistance mechanisms to advance SCLC research.
We welcome submissions about, but limited to the following:
• Multi-omics analyses of SCLC
• Genomic and transcriptomic landscapes
• Mechanisms of therapeutic resistance
• Novel therapeutic targets and signalling pathways
• Biomarker discovery
• Strategies to enhance immunotherapy efficacy
Researchers are encouraged to submit their work to help define the molecular underpinnings of SCLC and drive advancements in treatment strategies.
Submit your manuscript to this collection through the participating journal.
-
Saman Zeeshan
Assistant Professor, University of Missouri, United States. With a PhD in Bioinformatics and over a decade of academic and industry experience, Prof. Saman Zeeshan specializes in cancer biology. Her research spans multiomics disease analysis, isoform characterization in aggressive cancers, and innovative projects in collaboration with NCI. She has also applied bioinformatics to study tumor microenvironment changes. Her goal is to integrate genomics, immunology, and machine learning for novel cancer biomarkers.
